⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Novel Risk Factors for Predicting Immune-effector Cell Associated Neurotoxicity Syndrome (ICANS) (P3-14.001)

A Friedman Ceren Tozlu Christian Gordillo Ran Reshef Sarah Wesley

View Full Paper

Ask AI

Bookmark

Share

Abstract

To characterize novel risk factors for the development of ICANS after treatment with chimeric antigen receptor (CAR)-T Cell therapy for management of cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Friedman et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677c8a https://doi.org/10.1212/wnl.0000000000204489

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Immune effector cell-associated neurotoxicity syndrome: integrative mechanisms, predictive biomarkers, and translational pathways for prevention in CAR T-cell therapyHuman Clinical Trial · 2026 · 7 citations
2Risk stratification for immune effector cell-associated neurotoxicity syndrome in patients receiving chimeric antigen receptor T cell therapy.2024 · 2 citations
3CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells2024 · 31 citations
4Novel Treatment Modality for Chimeric Antigen Receptor T-cell Therapy Complications: A Case Report2024
5Beyond the Typical ICANS: Characterizing Non-ICANS Neurological Complications in CAR-T Therapy – A Retrospective AnalysisCohort Study · 2026